Comprehensive Financial Consultants Institutional Inc. bought a new position in shares of Pfizer Inc. (NYSE: PFE – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,811 shares of the biopharmaceutical company stock, valued at approximately $ 277,000.
Other institutional investors also recently bought and sold shares of the company. State Street Corp grew its holdings in Pfizer by 1.8% in the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company stock valued at $ 16,818,434,000 after purchasing an additional 5,013,651 shares during the period. Geode Capital Management LLC grew its holdings in Pfizer by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company stock valued at $ 5,952,333,000 after purchasing an additional 1,471,980 shares during the period. Norges Bank acquired a new stake in Pfizer in the fourth quarter valued at approximately $ 3,351,891,000. Morgan Stanley grew its holdings in Pfizer by 3.4% in the second quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company stock valued at $ 1,875,532,000 after purchasing an additional 1,582,052 shares during the period. Finally, Nuveen Asset Management LLC grew its holdings in Pfizer by 18.0% in the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company stock valued at $ 1,658,518,000 after purchasing an additional 4,278,167 shares during the period. 66.50% of the stock is currently owned by hedge funds and other institutional investors.
PFE has been the topic of several research analyst reports. Morgan Stanley initiated coverage on Pfizer in a report on Wednesday, April 6th. They issued an “equal weight” rating and a $ 55.00 price objective on the stock. Citigroup raised their price objective on Pfizer from $ 46.00 to $ 57.00 and gave the company a “neutral” rating in a report on Tuesday, April 5th. The Goldman Sachs Group set a $ 51.00 target price on Pfizer in a research report on Wednesday, May 25th. JPMorgan Chase & Co. set a $ 57.00 target price on Pfizer in a research report on Tuesday, May 3rd. Finally, Wells Fargo & Company decreased their target price on Pfizer from $ 60.00 to $ 55.00 in a research report on Wednesday, May 4th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Buy” and a consensus target price of $ 57.26.
NYSE: PFE opened at $ 46.53 on Friday. Pfizer Inc. has a 52 week low of $ 38.70 and a 52 week high of $ 61.71. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $ 261.08 billion, a P / E ratio of 10.67, a P / E / G ratio of 0.58 and a beta of 0.76. The stock’s fifty day moving average is $ 50.90 and its two-hundred day moving average is $ 52.34.
Pfizer (NYSE: PFE – Get Rating) last posted its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 EPS for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $ 25.66 billion during the quarter, compared to analysts’ expectations of $ 24.73 billion. During the same quarter in the prior year, the firm earned $ 0.93 EPS. Pfizer’s revenue for the quarter was up 76.8% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 6.61 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were given a $ 0.40 dividend. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $ 1.60 dividend on an annualized basis and a yield of 3.44%. Pfizer’s dividend payout ratio is currently 36.70%.
In related news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $ 53.96, for a total transaction of $ 227,603.28. Following the completion of the transaction, the senior vice president now directly owns 10,846 shares of the company stock, valued at approximately $ 585,250.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jennifer B. Damico sold 4,000 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the transaction, the senior vice president now directly owns 15,064 shares of the company stock, valued at $ 760,732. The disclosure for this sale can be found here. Insiders sold 41,126 shares of company stock worth $ 2,075,003 in the last 90 days. Company insiders own 0.05% of the company stock.
Pfizer Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.